Insider · CIK 0001586707

Hirsch Andrew

Reports to the SEC for 4 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001586707

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-17	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+51.7K sh	—	—	51,700
2026-02-15	CCCCC4 Therapeutics, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−9,057 sh	$1.89	−$17.1K	1,074,934
2026-02-15	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+20.4K sh	—	—	1,083,991
2026-02-14	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+81.7K sh	—	—	1,123,145
2026-02-14	CCCCC4 Therapeutics, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−39.2K sh	$1.89	−$74K	1,083,991
2026-02-13	CCCCC4 Therapeutics, Inc.A Award	Director, President & CEO	AAward	+700K sh	—	—	1,123,145
2025-06-06	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+37.5K sh	—	—	37,500
2025-02-15	CCCCC4 Therapeutics, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−9,370 sh	$3.18	−$29.8K	423,145
2025-02-14	CCCCC4 Therapeutics, Inc.A Award	Director, President & CEO	AAward	+224K sh	—	—	445,362
2025-02-14	CCCCC4 Therapeutics, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−12.8K sh	$3.18	−$40.9K	432,515
2025-02-14	CCCCC4 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+335K sh	—	—	335,300
2024-11-07	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+12.5K sh	—	—	227,412
2024-11-07	CCCCC4 Therapeutics, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−5,550 sh	$6.04	−$33.5K	221,862
2024-11-07	CCCCC4 Therapeutics, Inc. · Performance Restricted Stock UnitsM Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−12.5K sh	—	—	35,000
2024-09-16	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+7,500 sh	—	—	218,241
2024-09-16	CCCCC4 Therapeutics, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−3,329 sh	$6.36	−$21.2K	214,912
2024-09-16	CCCCC4 Therapeutics, Inc. · Performance Restricted Stock UnitsM Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−7,500 sh	—	—	47,500
2024-05-30	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2024-02-15	CCCCC4 Therapeutics, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−6,560 sh	$7.90	−$51.8K	210,741
2024-02-14	CCCCC4 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+466K sh	—	—	465,500
2024-02-14	CCCCC4 Therapeutics, Inc.A Award	Director, President & CEO	AAward	+103K sh	—	—	217,301
2023-09-18	CCCCC4 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+490K sh	—	—	489,600
2023-08-30	CCCCC4 Therapeutics, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−2,205 sh	$2.93	−$6,460.65	113,901
2023-08-30	CCCCC4 Therapeutics, Inc. · Performance Restricted Stock UnitsM Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−7,500 sh	—	—	55,000
2023-08-30	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+7,500 sh	—	—	116,106
2023-06-01	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2023-02-15	CCCCC4 Therapeutics, Inc.A Award	Director, President & CEO	AAward	+81.6K sh	—	—	108,606
2023-02-15	CCCCC4 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+367K sh	—	—	367,200
2023-01-30	CCCCC4 Therapeutics, Inc. · Performance Restricted Stock UnitsM Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−12.5K sh	—	—	62,500
2023-01-30	CCCCC4 Therapeutics, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−4,319 sh	$7.78	−$33.6K	27,006
2023-01-30	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+12.5K sh	—	—	31,325
2022-06-09	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2022-05-26	CCCCC4 Therapeutics, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−3,675 sh	$7.01	−$25.8K	18,825
2022-05-25	CCCCC4 Therapeutics, Inc. · Performance Restricted Stock UnitsM Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−12.5K sh	—	—	75,000
2022-05-25	CCCCC4 Therapeutics, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+12.5K sh	—	—	22,500
2022-04-12	CCCCC4 Therapeutics, Inc.P Purchase	Director, President & CEO	PPurchase	+10K sh	$8.40	+$84K	10,000
2022-02-23	CCCCC4 Therapeutics, Inc. · Performance Restricted Stock UnitsA Award	Director, President & CEO	AAward	+87.5K sh	—	—	87,500
2021-06-03	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+11.5K sh	—	—	11,538
2020-10-01	CCCCC4 Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+1.69M sh	—	—	1,691,672
2020-06-10	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+11.5K sh	—	—	11,538
2020-04-22	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,893 sh	—	—	11,785
2020-04-22	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,893 sh	—	—	26,199
2020-04-22	AGIOAGIOS PHARMACEUTICALS, INC.F Tax Payment	Chief Financial Officer	FTax Payment	−1,927 sh	$45.91	−$88.5K	24,272
2020-04-14	AGIOAGIOS PHARMACEUTICALS, INC.F Tax Payment	Chief Financial Officer	FTax Payment	−1,599 sh	$40.64	−$65K	20,306
2020-04-13	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,387 sh	—	—	10,775
2020-04-13	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,387 sh	—	—	21,905
2020-02-24	AGIOAGIOS PHARMACEUTICALS, INC.F Tax Payment	Chief Financial Officer	FTax Payment	−1,056 sh	$48.66	−$51.4K	16,518
2020-02-22	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,333 sh	—	—	17,574
2020-02-22	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,333 sh	—	—	6,667
2020-02-18	AGIOAGIOS PHARMACEUTICALS, INC.F Tax Payment	Chief Financial Officer	FTax Payment	−886 sh	$52.01	−$46.1K	14,241

Recent filings

Accepted (ET)
Jun 224
Hirsch Andrew0001650664-26-000070
SEC(opens sec.gov)
Feb 184
Hirsch Andrew0001470831-26-000177
SEC(opens sec.gov)
Jun 104
Hirsch Andrew0001650664-25-000099
SEC(opens sec.gov)
Feb 184
Hirsch Andrew0001662579-25-000021
SEC(opens sec.gov)
Nov 124
Hirsch Andrew0001662579-24-000100
SEC(opens sec.gov)
Sep 174
Hirsch Andrew0001662579-24-000084
SEC(opens sec.gov)
Jun 34
Hirsch Andrew0001650664-24-000068
SEC(opens sec.gov)
Feb 154
Hirsch Andrew0001662579-24-000020
SEC(opens sec.gov)

Companies

Address

C/O EDITAS MEDICINE, INC., 11 HURLEY ST.

CAMBRIDGE, MA, 02141